TABLE 1.
Baseline patient demographics.
| Number of patients | 292 |
|---|---|
| Age at treatment, median (range) | 50.5 years (20.0–72.0 years) |
| % Male | 263/292 (90.1%) |
| WBC (×106/L) | |
| ≤4000 | 61 (20.9%) |
| >4000 | 231 (79.1%) |
| RBC (×1012/L) | |
| ≤4 | 21 |
| >4 | 271 |
| PLT (×109/L) | |
| ≤100 | 57 |
| >100 | 235 |
| PT (s) | |
| ≤13 | 247 |
| >13 | 45 |
| TBil (μmol/L) | |
| ≤17.1 | 227 |
| >17.1 | 65 |
| ALB (g/L) | |
| ≤40 | 87 |
| >40 | 205 |
| ALT (U/L) | |
| ≤40 | 176 |
| >40 | 116 |
| AST (U/L) | |
| ≤35 | 168 |
| >35 | 124 |
| GGT (U/L) | |
| ≤50 | 84 |
| >50 | 208 |
| ALP (U/L) | |
| ≤150 | 275 |
| >150 | 17 |
| AFP (ng/mL) | |
| ≤400 | 201 |
| >400 | 91 |
| HBsAg | |
| positive | 269 |
| negative | 23 |
| HBsAb | |
| Positive | 230 |
| Negative | 62 |
| Child‐Pugh class | |
| A | 290 |
| B | 2 |
| Tumor diameter (cm) | |
| ≤5 | 220 |
| >5 | 72 |
Abbreviations: AFP, alpha‐fetoprotein; ALB, albumin; ALP, alkaline phosphatase; ALT, alanine aminotransferase; AST, aspartate aminotransferase; GGT, gamma‐glutamyl‐transferase; HBsAb, hepatitis B surface antibody; HBsAg, hepatitis B surface antigen; HCC, hepatocellular carcinoma; MVI, microvascular invasion; PLT, platelet; PT, prothrombin time; RBC, red blood cell; TBil, total bilirubin; WBC, white blood cell.